Physician profile
Chung E Tseng
NPI 1033187463
$11,189.41
in general payments reported to CMS, 2019-2025
28 companies · $997 in 2025
The $997 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,433 · 2020: $895 · 2021: $1,521 · 2022: $1,969 · 2023: $2,306 · 2024: $2,068 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,371.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,840.79 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,574.03 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Pfizer INC. | $1,481.21 | 2019-2025 | |
| Ucb, INC. | $967.77 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $920.18 | 2019-2025 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $841.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $735.59 | 2021-2025 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $359.94 | 2022-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $350.94 | 2021-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $114.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $114.65 | 2019-2021 | |
| Genentech USA, INC. | $108.78 | 2019-2020 | |
| Janssen Biotech, INC. | $101.60 | 2019-2025 | Tremfya |
| Fresenius Kabi USA, LLC | $95.80 | 2023-2025 | Idacio, Tyenne |
| Alexion Pharmaceuticals, INC. | $89.44 | 2022-2023 | Strensiq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.89 | 2023-2025 | Cyltezo, Jardiance |
| Horizon Therapeutics Plc | $69.94 | 2021-2022 | |
| Celgene Corporation | $55.70 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $48.57 | 2022 | |
| Bioventus LLC | $45.30 | 2020 | |
| Genentech, INC. | $39.95 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.17 | 2019 | |
| Sumitomo Pharma America, INC. | $26.75 | 2025 | Gemtesa |
| Mallinckrodt Hospital Products INC. | $25.99 | 2020 | |
| Sanofi-Aventis U.S. LLC | $24.13 | 2021 | |
| Sandoz INC. | $22.03 | 2023 | Hyrimoz |
| Genzyme Corporation | $17.05 | 2023 | |
| Hikma Pharmaceuticals USA | $15.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chung E Tseng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.